EI
BEAM icon

EAM Investors’s Beam Therapeutics BEAM Stock Holding History

EAM Investors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,440
Closed -$2.63M – 294
2021
Q2 		$2.63M Buy
+20,440
New +$1.63M 0.41% 68
2021
Q1 		– Sell
-23,642
Closed -$1.93M – 342
2020
Q4 		$1.93M Buy
+23,642
New +$1.16M 0.32% 128

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EAM Investors's BEAM Position: Q3 2021 in Review

EAM Investors sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 20,440 shares — an estimated $2.63M sold.

EAM Investors first reported a position in BEAM in Q4 2020 and held it in 2 quarters. The position peaked at $2.63M in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • EAM Investors reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • EAM Investors sold 20,440 Beam Therapeutics shares in Q3 2021, an estimated $2.63M.
  • EAM Investors first reported a position in Beam Therapeutics in Q4 2020 and held it in 2 quarters.
  • EAM Investors's Beam Therapeutics position peaked at $2.63M in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on EAM Investors's 13F filing for Q3 2021, filed 12 Nov 2021.